Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-erhalt-positive-chmp-stellungnahme-fur-kymriah-zur-behandlung-zweier-aggressiver-blutkrebsarten-ein-wichtiger-medizinischer-fortschritt-fur-patientinnen-und-patienten-europaErste CHMP-Stellungnahme zu CAR-T-Zell-Therapie bei zwei verschiedenen Indikationen: DLBCL bei Erwachsenen und B-Zell-ALL bei Kindern Der Antrag auf Marktzulassung (MAA) basiert auf zwei…
- https://www.novartis.com/news/media-releases/novartis-announces-intention-seek-shareholder-approval-100-spinoff-alcon-eye-care-devices-business-initiates-share-buyback-usd-5-bnAlcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create…
- https://www.novartis.com/news/media-releases/novartis-gibt-absicht-bekannt-die-genehmigung-der-aktionare-fur-einen-100igen-spin-des-geschafts-mit-ophthalmologischen-produkten-von-alcon-einzuholen-und-leitet-gleichzeitig-einen-aktienruckDie strategische Überprüfung von Alcon ergibt, dass ein 100%iger Spin-off im besten Interesse der Aktionäre ist und im Einklang mit der Strategie von Novartis steht, sich als…
- https://www.novartis.com/news/media-releases/novartis-annonce-son-intention-de-solliciter-lapprobation-des-actionnaires-pour-la-scission-100-dalcon-sa-division-de-produits-ophtalmologiques-et-initie-un-rachat-dactions-hauteur-dusdL'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-demonstrating-long-term-efficacy-safety-and-tolerability-aimovig-erenumab-patients-chronic-and-episodic-migraineResults from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
- https://www.novartis.com/news/media-releases/novartis-international-ag-global-study-novartis-and-european-migraine-and-headache-alliance-reveals-60-employed-people-severe-migraine-miss-average-week-work-monthStudy reveals migraine causes significant disruption to daily life and work, which could be managed with better preventive treatments and workplace solutions Migraine is estimated to cost up to…
- https://www.novartis.com/news/media-releases/novartis-clear-about-psoriasis-survey-data-highlights-challenges-psoriasis-patients-face-achieve-goal-clear-skinSurvey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
- https://www.novartis.com/news/media-releases/novartis-international-ag-alcon-acrysof-iq-panoptix-trifocal-intraocular-lens-shows-superior-visual-performance-head-head-trial-post-cataract-surgeryBetter visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1] Detailed findings presented at World Ophthalmology Congress 2018…
- https://www.novartis.com/news/media-releases/novartis-juliet-trial-kymriah-demonstrates-more-one-year-durability-responses-adults-relapsed-or-refractory-dlbclOverall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1] Patients had a 65% chance of being…
- https://www.novartis.com/news/media-releases/novartis-survey-uncovers-real-world-impact-immune-thrombocytopenia-or-itp-rare-blood-disease-patients-quality-lifeFindings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 263
- › Next page